LIFE-BTK Randomized Controlled Trial
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 261 participants.
Also called NCT04227899
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 261 participants
- Sponsor
- Registry
-
NCT04227899
-
- Other papers using this trial's data
- Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial
- Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
- Long-Term Outcomes of a Drug-Eluting Resorbable Scaffold vs Angioplasty in Infrapopliteal Chronic Limb-Threatening Ischemia: 3-Year Results From the LIFE-BTK Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United States, Australia, Hong Kong SAR China, New Zealand, Singapore, Taiwan
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT04227899. Randomized; single masking; primary purpose treatment. Start 2020-08-18 (actual); primary completion 2023-08-17 (actual). Results posted on 2024-09-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LIFE-BTK Randomized Controlled Trial
- Acronym
- LIFE-BTK
- Condition
- Critical Limb Ischemia (CLI)
- Intervention (Device)
- Esprit BTK Device
- Intervention (Device)
- Percutaneous Transluminal Angioplasty (PTA) Device
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct04227899- Content hash
26a9080806e46bd91c8f9f9991421aa82c27e22257220a3f0d1c6b9cbbeebe30